Format

Send to

Choose Destination
Ann Oncol. 2017 Mar 1;28(3):468-477. doi: 10.1093/annonc/mdw619.

Circulating tumor markers: harmonizing the yin and yang of CTCs and ctDNA for precision medicine.

Author information

1
Department of Pediatrics - Research, The University of Texas MD Anderson Cancer Center, Houston, USA.
2
Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA.
3
Department of Gastrointestinal (GI) Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA.

Abstract

Current trajectory of clinical care is heading in the direction of personalized medicine. In an ideal scenario, clinicians can obtain extensive diagnostic and prognostic information via minimally-invasive assays. Information available in the peripheral blood has the potential to bring us closer to this goal. In this review we highlight the contributions of circulating tumor cells and circulating tumor DNA and RNA (ctDNA/ctRNA) towards cancer therapeutic field. We discuss clinical relevance, summarize available and upcoming technologies, and hypothesize how future care could be impacted by a combined study.

KEYWORDS:

cell free DNA; cell free RNA; circulating tumor DNA; circulating tumor RNA; circulating tumor cells; exosomes

PMID:
27998963
PMCID:
PMC6246190
DOI:
10.1093/annonc/mdw619
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Silverchair Information Systems Icon for PubMed Central
Loading ...
Support Center